Opioid dependence: Rationale for and efficacy of existing and new treatments

Clinical Infectious Diseases

Volumn 43, Issue SUPPL. 4, 2006, Pages

  Fiellin, David A ^a   Friedland, Gerald H ^a   Gourevitch, Marc N ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CYTOCHROME P450; DIAMORPHINE; EFAVIRENZ; INDINAVIR; METHADONE; MU OPIATE RECEPTOR AGONIST; OPIATE; OPIATE AGONIST; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

CHRONIC DISEASE; COMA; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHADONE TREATMENT; NEUROBIOLOGY; OPIATE ADDICTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; REVIEW; VIRUS TRANSMISSION;

BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; METHADONE; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PROGNOSIS; RISK ASSESSMENT; SUBSTANCE ABUSE DETECTION; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 33845411086     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/508180     Document Type: Review

References (55)

1. Nestler EJ, Aghajanian GK. Molecular and cellular basis of addiction. Science 1997; 278:58-63.
2. Vocci FJ, Acri J, Elkashef A. Medication development for addictive disorders: the state of the science. Am J Psychiatry 2005; 162:1432-40.
3. Nestler EJ. Basic neurobiology of opiate addiction. In: Stine SM, Kosten TR, eds. New treatments for opiate dependence. New York: The Guilford Press, 1997:286.
4. Nestler EJ. Molecular mechanisms of drug addiction. Neuropharmacology 2004; 47(Suppl 1):24-32.
5. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349:975-86.
6. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 2005; 294:903-13.
7. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003; 361:662-8.
8. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348:1786-95.
9. O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005; 294:961-3.
10. Dole VP. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193:646-50.
11. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med 1966; 118:304-9.
12. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA 1998; 280:1936-43.
13. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991.
14. Gunne L, Gronbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend 1981; 7:249-56.
15. Newman RG, Whitehill WB. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 2:485-8.
16. Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychol Addict Behav 1997; 11:261-78.
17. Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep 1998; 113(Suppl):97-106.
18. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993; 6:1049-56.
19. Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005; 41:891-6.
20. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005; 100:150-8.
21. D'Aunno T, Pollack HA. Changes in methadone treatment practices: results from a national panel study, 1988-2000. JAMA 2002; 288:850-6.
22. D'Aunno TD, Vaughn TE. Variations in methadone treatment practices. JAMA 1992; 267:253-8.
23. Caplehorn JRM, Bell J. Methadone dosage and retention of patients in maintenance treatment. Med J Aust 1991; 154:195-9.
24. Caplehorn JRM, Bell J, Kleinbaum DG, Gebski VJ. Methadone dose and heroin use during maintenance treatment. Addiction 1993; 88:119-24.
25. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281:1000-5.
26. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23-37.
27. Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002; 137:688-92.
28. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA 2001; 286:1724-31.
29. King VL, Stoller KB, Hayes M, et al. A multicenter randomized evaluation of methadone medical maintenance. Drug Alcohol Depend 2002; 65:137-48.
30. Merrill JO, Jackson TR, Schulman BA, et al. Methadone medical maintenance in primary care: an implementation evaluation. J Gen Intern Med 2005; 20:344-9.
31. Salsitz EA, Joseph H, Frank B, et al. Methadone medical maintenance (MMM): treating chronic opioid dependence in private medical practice - a summary report (1983-1998). Mt Sinai J Med 2000; 67:388-97.
32. Schwartz RP, Brooner RK, Montoya ID, Currens M, Hayes M. A 12-year follow-up of a methadone medical maintenance program. Am J Addict 1999; 8:293-9.
33. Senay EC, Barthwell AG, Marks R, Boros P, Gillman D, White G. Medical maintenance: a pilot study. J Addict Dis 1993; 12:59-76.
34. Drug Addiction Treatment Act of 2000. Public Law 106-310, title XXXV, sections 3501-3502, 2000. Available at: http://buprenorphine.samhsa.gov/data. html. Accessed 6 November 2006.
35. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 54:1215-28.
36. Fudala PJ, Jaffe JH, Dax EM, Johnson RE. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47:525-34.
37. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995; 40:27-35.
38. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267:2750-5.
39. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401-7.
40. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology (Berl) 1994; 116:401-6.
41. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181:358-64.
42. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343:1290-7.
43. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93:475-86.
44. Kreek MJ. Drug interactions with methadone in humans. NIDA Res Monogr 1986; 68:193-225.
45. Kreek MJ. Opiate-ethanol interactions: implications for the biological basis and treatment of combined addictive diseases. NIDA Res Monogr 1988; 81:428-39.
46. Iribarne C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998; 26:257-60.
47. Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13:957-62.
48. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999; 20:147-69.
49. Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43(Suppl 4):S216-23 (in this supplement).
50. McCance-Katz EF, Rainey PM, Friedland G, Kosten TR, Jatlow P. Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001; 10:296-307.
51. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:435-43.
52. McCance-Katz EF, Pade P, Friedland G, Morse G, Moody D, Rainey PM. Efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid dependent individuals [abstract 653]. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections (Boston). Alexandria, VA: Foundation of Retrovirology and Human Health, 2005.
53. Hewitt DJ, McDonald M, Portenoy RK, Rosenfeld B, Passik S, Breitbart W. Pain syndromes and etiologies in ambulatory AIDS patients. Pain 1997; 70:117-23.
54. Breitbart W, Rosenfeld, B, Passik SD, Kaim M, Funesti-Esch J, Stein K. A comparison of pain report and adequacy of analgesic therapy in ambulatory AIDS patients with and without a history of substance abuse. Pain 1997; 72:235-43.
55. Breitbart W, Rosenfeld BD, Passik SD, McDonald MV, Thaler H, Portenoy RK. The under-treatment of pain in ambulatory AIDS patients. Pain 1996; 65:243-9.